Drug intelligence / Profile preview

GST-MDA-7

Development stage
Preclinical
Lead developer
Virginia Commonwealth University
Modality
Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration
Intravenous, Intratumoral
01

Overview

GST-MDA-7 is a recombinant fusion protein consisting of the cytokine Melanoma Differentiation Associated gene-7 (MDA-7), also known as Interleukin-24 (IL-24), fused to a Glutathione S-transferase (GST) tag. MDA-7/IL-24 is a unique member of the IL-10 cytokine family that demonstrates potent and selective anti-tumor activity by inducing apoptosis in a broad spectrum of cancer cells while remaining non-toxic to normal cells. The GST-tagged version is frequently utilized in laboratory research to elucidate the biochemical signaling pathways of the cytokine. Its mechanism of action involves the induction of endoplasmic reticulum (ER) stress and the activation of the CD95 (Fas) death receptor pathway through a ceramide-dependent mechanism. This leads to the activation of pro-apoptotic signaling molecules such as PERK, p38 MAPK, and JNK, while simultaneously inhibiting survival signals like ERK 1/2, ultimately resulting in caspase-mediated cell death.

Other names
Glutathione S-transferase-MDA-7GST-IL-24GST-IL24GST-IL 24GST-mda-7/IL-24mda-7/IL-24
02

Targets

IL20RA/IL20RB (Interleukin-20 Receptor)HSPA5 (Heat shock protein family A member 5)EIF2AK3 (Pkr-like endoplasmic reticulum kinase)TNFR (TNF receptor family)IL-22R1/IL-20R2 (Interleukin-22 receptor subunit alpha-1/Interleukin-20 receptor subunit beta heterodimer)

Beyond the preview

Go deeper on GST-MDA-7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GST-MDA-7.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call